Asymptomatic carriers of germline ERCC6L2 variants should undergo regular hematologic surveillance, including bone marrow testing, cytogenetic analysis, and tumor-based profiling, with a focus on detecting somatic TP53 variants, as these may progress to acute myeloid leukemia (AML) (91). The gene discussed is ERCC6L2; the disease is acute myeloid leukemia.